Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 943.45 INR
Change Today 0.00 / 0.00%
Volume 0.0
PIEL On Other Exchanges
Symbol
Exchange
Natl India
OTC US
As of 7:06 AM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

piramal enterprises ltd (PIEL) Snapshot

Open
976.25
Previous Close
971.05
Day High
979.00
Day Low
925.00
52 Week High
04/15/15 - 1,014
52 Week Low
04/30/14 - 538.05
Market Cap
162.8B
Average Volume 10 Days
120.4K
EPS TTM
-29.06
Shares Outstanding
172.6M
EX-Date
07/15/14
P/E TM
--
Dividend
52.50
Dividend Yield
5.56%
Current Stock Chart for PIRAMAL ENTERPRISES LTD (PIEL)

Related News

No related news articles were found.

piramal enterprises ltd (PIEL) Related Businessweek News

No Related Businessweek News Found

piramal enterprises ltd (PIEL) Details

Piramal Enterprises Limited primarily manufactures and sells own and traded bulk drugs and formulations in India and internationally. It operates through three segments: Pharmaceuticals Businesses, Financial Services Businesses, and Information Management Business. The company provides custom manufacturing services across the entire drug lifecycle ranging from development and commercial manufacturing to off-patent supplies of active pharmaceutical ingredients and formulations. It also manufactures and sells inhalation anaesthetics, such as Halothane, Isoflurane, and Sevoflurane; Propofol; and plasma volume expanders, including Polygeline. In addition, the company offers vitamins and nutrition, analgesics, dermatological, antacids, and cough and cold products under various brands, such as Saridon, Lacto Calamine, i-Pill, Itchmosol, Supractiv Complete, Polycrol, i-Sure, i-Can, Jungle Magic, Tetmosol, and Triactiv; and lipids and immunoturbidimetric HbA1c kits to bio-chemistry analysers, hematology analysers, and diasys range of reagents. Further, it develops various medicines that are in Phase I trials comprising GPR40 agonist - P11187, an oral anti-diabetic molecule; P7435, a DGAT1 inhibitor that addresses multiple aspects of metabolic syndrome; and P1446 and P7170 for oncology. Additionally, the company offers Neuraceq, an imaging agent; BST-CarGel, a bio-scaffold for cartilage regeneration; and focuses on the research and commercialization of natural products and herbal medicines. It also offers finance to real estate developers; structured finance transaction services for infrastructure companies; and data analytics services to pharmaceutical, medical device, managed care, and other healthcare industry customers, as well as is engaged in NBFC operations. The company was formerly known as Piramal Healthcare Limited and changed its name to Piramal Enterprises Limited in July 2012. Piramal Enterprises Limited was incorporated in 1947 and is based in Mumbai, India.

4,984 Employees
Last Reported Date: 06/26/14
Founded in 1947

piramal enterprises ltd (PIEL) Top Compensated Officers

Chairman, Member of Nomination & Remuneration...
Total Annual Compensation: 63.0M
Chief Operating Officer, Executive Director a...
Total Annual Compensation: 35.3M
Vice Chairperson
Total Annual Compensation: 30.1M
General Manager of Strategic Marketing, Execu...
Total Annual Compensation: 21.3M
Compensation as of Fiscal Year 2014.

piramal enterprises ltd (PIEL) Key Developments

Piramal Enterprises In Talks To Acquire Stake in SuperHiWay

Piramal Enterprises Limited (BSE:500302) reportedly is seeking acquisition of Health SuperHiway Pvt. Ltd. from Apollo Hospitals Enterprise Limited (BSE:508869). “Piramal Enterprises is in advanced negotiations with the Reddys of Apollo Hospitals to buy the latter's fledgling healthcare software venture Health Super Hi-Way, in what would be a unique marriage between healthcare and Big Data if it goes ahead. Apollo patriarch Prathap C Reddy and his four daughters, who control and run India's largest hospital chain Apollo Hospitals, are all set to sell their majority stake in the company to Piramal, ending months of protracted negotiations,” as per multiple sources who are directly involved. Piramal is expected to pick up an initial 5% stake for INR 50 million –INR 80 million, highlighting its interest. Upon submission of a detailed and feasible business plan, this will be raised to 60-80%, valuing the company at close to INR 2.2 billion – INR 2.5 billion. Sources added that Piramal is open to spending INR 1 billion –INR 1.2 billion to take control of the venture. The Reddys are likely to stay invested, but as a junior partner. Currently, the Reddy family and Apollo Hospital investment vehicles - PCR Investments Ltd. and Indian Hospitals Corporation Limited- together hold over 90% of the company. According to one of the persons cited, “Piramal was initially keen on a takeover but has agreed to a controlling stake to the accommodate Reddys' intent to stay invested in the eight-year-old company.” “The deal is not through yet. I'd say this is a strategic partnership, meaning Apollo is invested in the idea behind Health HiWay," a top executive with the healthcare chain told Economic Times. Other executive confirmed talks are nearing the deal-signing stage, adding that the share transfer will take about three weeks.

Piramal Enterprises Limited Reports Unaudited Standalone and Consolidated Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014

Piramal Enterprises Limited reported unaudited standalone and consolidated earnings results for the third quarter and nine months ended December 31, 2014. For the quarter, on standalone basis, the company reported net sales/income from operations of INR 6,446.7 million against INR 4,791.1 million a year ago. Profit from operations before other income, other income, finance cost and exceptional items was INR 1,365 million against INR 570.8 million a year ago. Loss from ordinary activities before tax was INR 22,322.9 million against INR 821.4 million a year ago. Net loss was INR 22,383 million or INR 129.7 per basic and diluted share against INR 821.4 million or INR 4.8 per basic and diluted share a year ago. For the nine months, on standalone basis, the company reported net sales/income from operations of INR 16,105.6 million against INR 13,356.9 million a year ago. Profit from operations before other income, finance cost and exceptional items was INR 2,507.7 million against INR 1,171 million a year ago. Profit from ordinary activities before tax was INR 5,578.2 million against loss of INR 1,686.1 million a year ago. Net profit was INR 3,000.5 million or INR 17.4 per basic and diluted share against loss of INR 1,686.1 million or INR 9.8 per basic and diluted share a year ago. For the quarter, on consolidated basis, the company reported net sales/income from operations of INR 13,814.5 million against INR 12,761.2 million a year ago. Profit from operations before other income, other income, finance cost and exceptional items was INR 2,402.3 million against INR 2,126.1 million a year ago. Profit from ordinary activities before tax was INR 2,417.8 million against loss of INR 6.0 million a year ago. Net profit was INR 2,490.2 million or INR 14.4 per basic and diluted share before and after extraordinary items against loss of INR 111.4 million or INR 0.7 per basic and diluted share before and after extraordinary items a year ago. OPBITDA was INR 3,200 million against INR 2,760 million a year ago. Profit before tax & exceptional items were INR 2,070 million against INR 20 million a year ago. Operating profit was driven by strong revenue performance across businesses during the quarter and fall in R&D expenses. R&D expenses were lower during the quarter on account of scaling back of investments in NCE research in second quarter of the fiscal 2015. The increase in net profit was mainly on account of improved operating performance, lower interest cost due to reduction in long term debt, exceptional gain and higher share of income from associates, partly offset by marginal increase in depreciation and higher tax expense. For the year to date, on consolidated basis, the company reported net sales/income from operations of INR 37,814.9 million against INR 33,540.5 million a year ago. Profit from operations before other income, other income, finance cost and exceptional items was INR 4,738.3 million against INR 3,860.2 million a year ago. Profit from ordinary activities before tax was INR 29,535.8 million against loss of INR 1,514.8 million a year ago. Net profit was INR 27,545.5 million or INR 159.6 per basic and diluted share before and after extraordinary items against loss of INR 1,900.6 million or INR 11.0 per basic and diluted share before and after extraordinary items a year ago. OPBITDA was INR 6,930 million against INR 5,680 million a year ago. Profit before tax & exceptional items were INR 2,620 million against loss of INR 1,580 million a year ago.

Piramal Enterprises Limited, Board Meeting, Feb 09, 2015

Piramal Enterprises Limited, Board Meeting, Feb 09, 2015. Agenda: To consider and approve the unaudited financial results (consolidated and standalone) of the company for the quarter and nine months ended December 31, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PIEL:IN 943.45 INR -27.60

PIEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biocon Ltd 465.80 INR -5.60
Cambrex Corp $40.98 USD -0.75
Divi's Laboratories Ltd 1,894 INR -3.10
Jubilant Life Sciences Ltd 167.45 INR -4.70
Torrent Pharmaceuticals Ltd 1,281 INR -28.15
View Industry Companies
 

Industry Analysis

PIEL

Industry Average

Valuation PIEL Industry Range
Price/Earnings 6.7x
Price/Sales 3.3x
Price/Book 1.4x
Price/Cash Flow 6.0x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PIRAMAL ENTERPRISES LTD, please visit www.piramal.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.